Developing contrast-enhanced optical coherence tomography (OCT) techniques is important for specific imaging of tissue lesions, molecular imaging, cell-tracking, and highly sensitive microangiography and lymphangiography. Multiplexed OCT imaging in the second near infrared (NIR-II) window is highly desirable since it allows simultaneous imaging and tracking of multiple biological events in high resolution with deeper tissue penetration in vivo.
Introduction
Optical coherence tomography (OCT) is an emerging imaging modality to investigate tissue microstructural morphology. It allows three-dimensional real time in vivo imaging at cellular-scale resolution and several-millimeter tissue penetration depth. 1 However, since most tissue, cells and biomolecules lack intrinsic OCT contrast, it is necessary to develop contrastenhanced OCT techniques to investigate the functional processes of the living body, such as growth of lesioned tissue, cell dynamics, and flows in vasculature. 2, 3 Thus far, quite a few materials have been studied as exogenous OCT contrast agents, including microspheres, 4, 5 microbubbles, 6, 7 magnetic nanoparticles 8 and plasmonic nanoparticles. [9] [10] [11] [12] Among them, plasmonic gold nanoparticles are of particular interest due to their highly tunable shape, size, optical properties, facile surface chemistry and excellent biocompatibility. 13 Nevertheless, very few reported OCT contrast agents have shown the capability of multiplexing, especially in the second near infrared (NIR-II) window (1100-1400 nm), which allows deeper tissue penetration. 14 Recently , we reported that gold nanoprisms can be used as OCT contrast agents in the NIR-II window due to their strong scattering at 1385 nm. 12 In this work, we demonstrate that gold nanobipyramids (GNBPs) with two distinct aspect ratios and surface plasmon resonances can work as OCT contrast agents in the NIR-II window for multiplexed imaging. We show that by subcutaneously injecting two different types of GNBPs, GNBP-I and GNBP-II, two separate lymphatic flows can be visualized simultaneously in a live mouse ear using a custom dual-band OCT spectral signal processing algorithm described in our previous work. 11 The contrast agents also allow us to map lymphatic flows from two different drainage basins-tumor and peritumoral tissues into the same lymph node. By injecting GNBP-I intratumorally and GNBP-II subcutaneously, the tumor and peritumoral lymphatic drainage pathways can be visualized simultaneously. Our multiplexed imaging shows that a melanoma tumor implanted in the mouse ear drains the lymphatic fluid not only in the cervical direction, but also in all other directions.
Subcutaneously injected contrast agents appear not only in the peritumoral lymphatic vessels, but also inside the tumor. We also show that after injection, we can track the contrast agents in different organs of the body. In vivo and ex vivo lymph node imaging show that the peritumoral lymphatic vessels drain the contrast agents to the deep cervical lymph nodes.
Results and discussion
GNBPs were prepared according to the method described in Supporting Information. The size and surface morphology of the as-synthesized GNBPs were studied by transmission electron microscopy (TEM). GNBP-I and GNBP-II show similar surface morphology, but different dimensions and aspect ratios (Figure 1a, b ). GNBP-I has an average length of 137 nm and width of 22 nm, while GNBP-II is larger with an average length of 177 nm and width of 25 nm. These dimensions correspond to aspect ratios of 6.2 and 7.1 for GNBP-I and GNBP-II, respectively ( Figure 1c ). The NIR spectra show that the surface plasmon resonances of GNBP-I and GNBP-II are at 1225 nm and 1415 nm, respectively ( Figure 1d ).
To take advantage of the unique spectral characteristics of GNPB-I and GNBP-II, we use a custom dual band spectral analysis algorithm 11 to detect the nanoparticles. The algorithm divides the OCT interferogram in the source bandwidth into two sub-bands: Band I (1190-1271 nm) and Band II (1272-1365 nm) (see method section in Supporting Information). The interferogram in each sub-band is reconstructed independently to create two OCT images in the spectral domain. The Band II OCT image is then subtracted from the Band I OCT image to obtain the spectral contrast signal. To measure the spectral contrast signal intensity as a function of the concentration of each type of GNBP, we imaged GNBP-I and GNBP-II with a broad range of concentrations in capillary tubes using mouse whole blood as reference. As expected, we observe two distinct spectral contrast signals for GNBP-I and GNBP-II in the reconstructed spectral OCT B-scan images color-coded by a hue-saturation-value (HSV) scheme (Figure 2a Figure S3 ). The multidirectional lymphatic drainage could be caused by malfunctional lymphatic valves in the peritumoral lymphatic vessels. 17 We also show that the peritumoral lymphatic vessels have larger average vascular diameters compared to normal lymphatic vessels ( Figure S4 ), possibly resulting from hyperplasia. 17, 18 Following subcutaneous injection of PEGylated GNBP-II, we noticed that negative spectral contrast signals can be visualized not only in peritumoral lymphatic vessels (Figure 5f ), but also in the tumor (arrows in Figure 5f , i). This result implies that the subcutaneously injected contrast agents infiltrated into the tumor lymphatic vessels. The cross-sectional compound image reveals that GNBP-II appears in both superficial and deep tumor lymphangia, which are measured to be 50 and 160 µm below the skin surface (arrows in Figure 5i ). The superficial lymphangion could correspond to lymphatic vessels in the dermis tissue surrounding the melanoma tumor. However, the lymphangion located at 160 µm below the skin surface Figure S5 .
To further study the lymphatic drainage pathways of the contrast agents injected into the two different basins, we imaged the deep cervical lymph node on the ipsilateral side of the mouse ear pre-injection and after each injection. At pre-injection, no OCT signals can be observed in the lymphatic vessels of the lymph node on the cross-sectional compound image (arrow in Figure 5j ). 30 min after intratumoral injection, positive spectral contrast signals can be observed in the lymphatic vessel in the lymph node (Figure 5k ). Thirty min after subcutaneous injection, negative spectral contrast signals can be observed in the same lymphatic vessel ( Figure   5l ). The result corroborates that after intratumoral and subcutaneous injection, each contrast agent was drained into the peritumoral lymphatic vessels and then collected by the deep cervical lymph node.
After the in vivo imaging of the melanoma tumor-implanted mouse, we resected deep cervical lymph nodes on both the ipsilateral and contralateral sides (Figure 6 , a-c) and conducted three-dimensional (3-D) lymphangiography ex vivo. In the spectral 3-D OCT lymphangiograms and cross-sectional compound images, the spectral contrast signals can be visualized in the lymphatic vessels of the ipsilateral cervical lymph node (Figure 6d ,e, Movie S1), but not in the contralateral lymph node of the mouse (Figure 6f The novel NIR-II OCT contrast agents and multiplexing technique we report here provide a platform that opens many opportunities for biological and clinical research in the future, including multiplexed cell tracking and molecular imaging in live subjects. In the lymphatic research field, this technique could be used for imaging tumor lymph node metastasis of heterogeneous tumor cells (i.e., tumor cells expressing different biomarkers). It could also be employed for molecular imaging to study the dynamic expression of various lymph endothelial cell receptors (i.e., lymphatic vessel endothelial hyaluronan receptor 1 or LYVE-1, and vascular endothelial growth factor receptor 3 or VEGFR-3) in tumor angiogenic lymphatic vessels and lymph nodes. By applying this technique to in vivo brain imaging, we believe it can further unravel the mystery and complexity of brain lymphatic drainage pathways, which play important roles in neuron inflammation and neurodegenerative diseases. 
